Program
Corporate Symposium
Corporate Symposium 1
By Novo Nordisk

Thursday 3 September

09:00-10:00

Liraglutide 3.0mg: Practical discussion with obesity clinician Jung Min CHOIJM Network Family Medicine, Korea


Corporate Symposium 2
By Alvogen

Thursday 3 September

10:00-11:00

TBDTBDTBD


Corporate Symposium 3
By MSD

Thursday 3 September

11:00-12:00

The latest evidence of SGLT2I for type 2 diabetes patients 吏꾪씎슜쟾遺곷븰援 蹂묒썝


Corporate Symposium 4
By Hanmi

Thursday 3 September

13:30-15:00

TBDTBDTBD


Corporate Symposium 5
By Gwangdong

Thursday 3 September

13:30-15:00

Bupropion + Naltrexone 蹂듯빀젣: 肄섑듃씪釉뙿瑜 솢슜븳 鍮꾨쭔 移섎즺 源젙솚Nowon Eulji Medical Center, Eulji University, Korea


Corporate Symposium 6
By Inno.N

Thursday 3 September

13:30-15:00

Update on the diabetes management혻based on the treatment guideline 源以븘二쇱쓽 궡遺꾨퉬궗궡怨


Corporate Symposium 7
By Johnson & Johnson

Thursday 3 September

09:00~10:10

Mastering RYGB - Both as a primary and revisional surgery Ahmad ALYUniversity of Melbourne, Australia


Corporate Symposium 8
By Medtronic

Thursday 3 September

10:10-10:40

Procedure video 1: How i do it Lap. sleeve gastrectomy with duodenojejunal bypass Young Suk PARKSeoul National University, Korea
10:40-11:10

Procedure video 2: How i do it Lap. Roux-en-Y gastric bypass Ji Yeon PARKKyungpook National University, Korea
11:10-11:40

Procedure video 3: How i do it Lap. revisional surgery: MGB to RYGB Sang Hyun KIMSoonchunhyang University, Korea


Corporate Symposium 9 (K)
By JW Pharmaceutical

Thursday 3 September

19:00-19:30

All statins are the same in safety and outcome for Asian Sang Yong KIMDivision of Endocrinology and Metabolism, Chosun University, Korea


Corporate Symposium 10 (K)
By Dong-A ST

Thursday 3 September

19:30-20:00

New paradigm of glycemic variability: EVERGREEN studyIn-Kyung JEONGDepartment of Endocrinology and Metabolism, Kyung Hee University, Korea


Corporate Symposium 11
By Sanofi-Aventis

Friday 4 September

07:30-08:00

Challenging the injectable treatment paradigm in T2DM: Rationale for fixed-ratio co-formulation Su-Jin JEONG Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital


Corporate Symposium 12
By LG Chem

Friday 4 September

07:30-08:00

Solution for optimal glycemic control in early and advanced stages of type 2 diabetes Tae Jung OH Seoul National University, Korea


Corporate Symposium 13
By Olympus

Chairperson: Seung Wan RYU (Keimyung University, Korea)
Friday 4 September

07:30-08:00

Olympus ENG device - metabolic surgery Han Hong LEE The Catholic University of Korea, Korea


Corporate Symposium 14
By MSD

Friday 4 September

12:40-13:10

The latest option for the treatment of type 2 diabetes Hye Jin YOO Department of Endocrinology and Metabolism, Korea University, Korea


Corporate Symposium 15
By Alvogen

Friday 4 September

12:40-13:10

Observed improvements of comorbid conditions in obese patients utilizing combination phentermine plus topiramate extended release Santosh T. VARGHESE VIVUS Inc., USA


Corporate Symposium 16
By Medtronic

Chairperson: Soo Min AHN (Hallym University, Korea)
Friday 4 September

12:40-13:10

Bariatric training and education program in Australia Lilian KOW Adelaide Bariatric Centre, Australia


Corporate Symposium 17
By Daewoong Pharmaceutical

Friday 4 September

12:40-13:10

Clinical application of a new convenient continuous glucose monitoring device: FreeStyle Libre짰 Soo LIM Department of Internal Medicine, Seoul National University Bundang Hospital, Korea


Corporate Symposium 18
By Chong Kun Dang Pharmaceutical

Saturday 5 September

07:30-08:00

Qualified of new obesity drug through patient case Bo-Yeon KIM Division of Endocrinology and Metabolism, Soonchunhyang University, Korea


Corporate Symposium 19
By Handok

Saturday 5 September

07:30-08:00

The multiple benefits of SGLT-2i: Ideal option for Asian T2DM patients Sang Youl RHEE Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine


Corporate Symposium 20
By YUHAN

Saturday 5 September

07:30-08:00

The recent guideline based on glucose lowering drugs 씠쁺 꽌슱꽦紐⑤퀝썝 궡遺꾨퉬궡怨


Corporate Symposium 21
By Novo Nordisk

Saturday 5 September

12:30-13:00

Liraglutide: Key opportunities beyond weight reduction Changhee JUNG Department of Endocrinology and Metabolism, University of Ulsan, Korea


Corporate Symposium 22
By Eli Lilly and Company

Saturday 5 September

12:30-13:00

TBD Ted WU The Royal Prince Alfred Hospital, Australia


Corporate Symposium 23
By Johnson & Johnson

Chairperson: Jin-Jo KIM (Incheon St. Mary's Hospital, Catholic University, Korea)
Saturday 5 September

12:30-13:00

TBD Ali AMINIAN Cleveland Clinic, USA


Corporate Symposium 24
By Takeda Pharmaceutical

Saturday 5 September

12:30-13:00

The power of one pill, NesinaAct for T2DM patients with atherosclerosis Jae hyuk LEE Department of Endocrinology and Metabolism, Myongji Hospital, Korea